ID   HEC-59
AC   CVCL_2930
SY   HEC59; Hec59
DR   AddexBio; C0026001/42
DR   ArrayExpress; E-MTAB-2770
DR   BioGRID_ORCS_Cell_line; 717
DR   BioSample; SAMN03472458
DR   BioSample; SAMN03470882
DR   BioSample; SAMN10988108
DR   cancercelllines; CVCL_2930
DR   Cell_Model_Passport; SIDM01617
DR   Cosmic; 1070806
DR   Cosmic; 1223492
DR   Cosmic; 1576460
DR   Cosmic; 1622901
DR   Cosmic; 1696750
DR   Cosmic; 2030472
DR   DepMap; ACH-000994
DR   GEO; GSM887074
DR   GEO; GSM888144
DR   IARC_TP53; 20591
DR   JCRB; JCRB1120
DR   JCRB; NIHS0392
DR   LiGeA; CCLE_600
DR   PharmacoDB; HEC59_530_2019
DR   Progenetix; CVCL_2930
DR   Wikidata; Q54882265
RX   DOI=10.1007/978-4-431-53981-0_1;
RX   DOI=10.5795/jjscc.26.433;
RX   PubMed=2064198;
RX   PubMed=9000572;
RX   PubMed=10381137;
RX   PubMed=12227503;
RX   PubMed=15053063;
RX   PubMed=20944090;
RX   PubMed=22460905;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=28196595;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31978347;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Japanese.
CC   Doubling time: 24.3 hours (Note=At 152th passage) (DOI=10.5795/jjscc.26.433).
CC   HLA typing: A*24:02,24:02; B*40:06,40:06; C*08:01,08:01; DQA1*02:01,02:01; DRB1*04:66,04:66 (PubMed=26589293).
CC   Microsatellite instability: Instable (MSI) (PubMed=31068700).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Val (c.437C>T); Zygosity=Heterozygous (DepMap).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Tyr46His (c.136T>C); ClinVar=VCV001701143; Zygosity=Heterozygous (PubMed=20944090; DepMap).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Pro213Leufs (c.637_638insT) (c.637C>CT); Zygosity=Heterozygous (PubMed=20944090).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg233Ter (c.697C>T); ClinVar=VCV000007813; Zygosity=Heterozygous (PubMed=20944090; DepMap).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Heterozygous (PubMed=20944090; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser95Phe (c.284C>T); ClinVar=VCV001796813; Zygosity=Heterozygous (DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (PubMed=15053063; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=1.33%; Native American=0.09%; East Asian, North=79.33%; East Asian, South=17.72%; South Asian=0.28%; European, North=0%; European, South=1.25% (PubMed=30894373).
CC   Discontinued: JCRB; NIHS0392; true.
CC   Derived from site: In situ; Endometrium; UBERON=UBERON_0001295.
ST   Source(s): AddexBio; JCRB; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 9,10
ST   D13S317: 9,10,11
ST   D16S539: 11,12,13
ST   D18S51: 12,13
ST   D19S433: 12,13
ST   D21S11: 29,32
ST   D2S1338: 15,16
ST   D3S1358: 13,14,16,17
ST   D5S818: 10,11,12
ST   D7S820: 10,11,14
ST   D8S1179: 12,15
ST   FGA: 21,22,23
ST   Penta D: 9,10,11
ST   Penta E: 15,16
ST   TH01: 7,9.3
ST   TPOX: 11 (PubMed=25877200)
ST   TPOX: 11,14 (AddexBio; JCRB)
ST   vWA: 17,20,22
DI   NCIt; C7359; Endometrial adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 32
//
RX   DOI=10.1007/978-4-431-53981-0_1;
RA   Kuramoto H., Hamano M., Imai M., Fujisawa T., Kamata Y., Arai T.,
RA   Kawaguchi M.;
RT   "HEC-1 cells: establishment of an in vitro experimental system in
RT   endometrial carcinoma.";
RL   (In) Cell and molecular biology of endometrial carcinoma; Kuramoto H., Nishida M. (eds.); pp.3-34; Springer; Tokyo (2003).
//
RX   DOI=10.5795/jjscc.26.433;
RA   Morisawa T.;
RT   "The results of primary culture of endometrial adenocarcinoma and
RT   characterization of its established cell line.";
RL   Nihon Rinsho Saibo Gakkai Zasshi 26:433-442(1987).
//
RX   PubMed=2064198; DOI=10.1111/j.1749-6632.1991.tb37884.x;
RA   Kuramoto H., Nishida M., Morisawa T., Hamano M., Hata H., Kato Y.,
RA   Ohno E., Iida T.;
RT   "Establishment and characterization of human endometrial cancer cell
RT   lines.";
RL   Ann. N. Y. Acad. Sci. 622:402-421(1991).
//
RX   PubMed=9000572;
RA   Hoang J.-M., Cottu P.H., Thuille B., Salmon R.J., Thomas G.,
RA   Hamelin R.;
RT   "BAT-26, an indicator of the replication error phenotype in colorectal
RT   cancers and cell lines.";
RL   Cancer Res. 57:300-303(1997).
//
RX   PubMed=10381137; DOI=10.1016/s0304-3835(98)00270-5;
RA   Ohta H., Sakamoto H., Satoh K.;
RT   "In vitro effects of gonadotropin-releasing hormone (GnRH) analogue on
RT   cancer cell sensitivity to cis-platinum.";
RL   Cancer Lett. 134:111-118(1998).
//
RX   PubMed=12227503; DOI=10.1111/j.1749-0774.2002.tb00103.x;
RA   Kuramoto H., Hamano M., Imai M.;
RT   "HEC-1 cells.";
RL   Hum. Cell 15:81-95(2002).
//
RX   PubMed=15053063;
RA   Kamata Y., Watanabe J., Hata H., Hamano M., Kuramoto H.;
RT   "Quantitative study on the correlation between p53 gene mutation and
RT   its expression in endometrial carcinoma cell lines.";
RL   Eur. J. Gynaecol. Oncol. 25:55-60(2004).
//
RX   PubMed=20944090; DOI=10.1126/scitranslmed.3001538;
RA   Dedes K.J., Wetterskog D., Mendes-Pereira A.M., Natrajan R.,
RA   Lambros M.B., Geyer F.C., Vatcheva R., Savage K., Mackay A.,
RA   Lord C.J., Ashworth A., Reis-Filho J.S.;
RT   "PTEN deficiency in endometrioid endometrial adenocarcinomas predicts
RT   sensitivity to PARP inhibitors.";
RL   Sci. Transl. Med. 2:53ra75.1-53ra75.8(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//